ERBB2 and breast cancer: In HER2-positive patients with stage-I–III BC who received mastectomy, Lanning et al. found that trastuzumab did not decrease LRR risk in patients who did not receive PMRT, but it decreased LRR risk among those who received PMRT, suggesting that the greatest benefit is seen in a higher-risk subset of patients (8).